Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 14/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.68 |
| ▸ | SCN1A | P35498 | 2/20 | 0.68 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.68 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.65 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14237398 | 0.91 | SCN10A (0.83) | SCN10ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL263764 | 0.89 | SCN10A (0.86) | SCN10ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL261800 | 0.88 | SCN10A (1.00) | SCN10ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL264604 | 0.88 | SCN10A (0.81) | SCN10ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL263363 | 0.88 | SCN10A (0.81) | SCN10ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL14237460 | 0.86 | SCN10A (0.84) | SCN10ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL14237413 | 0.85 | SCN10A (0.74) | SCN10ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL2417774 | 0.85 | SCN10A (0.74) | SCN10ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL263595 | 0.84 | SCN10A (1.00) | SCN10ASCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL14237364 | 0.83 | SCN10A (1.00) | SCN10ASCN9ASCN1ASCN5ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183241-B1 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LTD (GB) | 2012-12-19 | — | — | EP | claimed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | claimed |
| JP-4657384-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| JP-2010526050-A | — | — | 2010-07-29 | — | — | JP | claimed |
| EP-2183241-A2 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | Pfizer Limited (GB) | 2010-05-12 | — | — | EP | claimed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | claimed |
| WO-2008135826-A2 | 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | claimed |
| EP-2183241-B1 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LTD (GB) | 2012-12-19 | — | — | EP | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048306-A1 | PYRIDINE DERIVATIVES | SDHA, P2RX4, P2RX3 | SCN10A 358/4885SCN9A 491/4885SCN1A 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.